Using a new adjuvant to enhance cancer peptide vaccines
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
This study is exploring a new way to make cancer vaccines work better by using special tiny particles that help boost the immune system, which could lead to a stronger defense against tumors for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10773013 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve the effectiveness of MHC-I-restricted peptide cancer vaccines by using a cobalt porphyrin nanoliposome adjuvant. The method involves mixing short peptide epitopes with these liposomes to create stable particles that can better stimulate the immune system. By enhancing the generation of antigen-specific T cells, this approach aims to provide a more effective cancer treatment option. Patients may benefit from a more robust immune response against their tumors through this innovative vaccination strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that express specific MHC-I restricted peptide antigens.
Not a fit: Patients whose tumors do not express the targeted MHC-I restricted peptides may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer vaccines that significantly improve patient outcomes.
How similar studies have performed: Previous research has shown promise in using similar adjuvant approaches to enhance immune responses, suggesting potential for success in this novel application.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Lovell, Jonathan F — State University of New York at Buffalo
- Study coordinator: Lovell, Jonathan F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.